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INTRODUCTION 
The paraoxonase (PON) gene family consists of three mem-
bers-PON1, PON2, and PON3-located adjacent to each
other on the long arm of chromosome 7 in humans. These
three human PON genes share approximately 60% identity
at the amino acid level and approximately 70% identity at
the nucleotide level. However among other mammalian spe-
cies, these three genes share 79-90% identity at the amino
acid level and 81-90% identity at the nucleotide level (1).
PON1 is synthesized in the liver and secreted in the blood,
where it associates with high-density lipoprotein (HDL).
Changes in HDL size and shape can strongly affect the bind-
ing affinity and stability of PON1 and result in reduced an-
tioxidative capacity (2). However, PON2 mRNA is more
widely expressed in nearly every human tissue including the
heart, kidney, liver, lung, placenta, small intestine, spleen,
stomach, and testis. Arterial wall Endothelial cells, smooth
muscle cells and macrophages of arterial wall are also known
to express PON2 (3). PON1 might play an important phys-
iological role in lipid metabolism through protecting against
the development of atherosclerosis. Many investigations have
provided considerable evidence for PON1 anti-atherogenic-
ity. Studies have shown that PON1 inhibits oxidation of HDL
and low-density lipoproteins (LDL) that preserve HDL func-
tion, increases cellular cholesterol efflux from macrophages
ameliorates effects of oxidized LDL, and decreases lipid per-
oxides in atherosclerotic lesions (2). 
The antioxidant and anti-inflammatory properties of PON2,
along with its intracellular localization, ubiquitous expres-
sion, and upregulation in times of oxidative stress, suggest an
important physiological role for PON2 in host defense against
atherosclerosis (3). Thus, PON2 plays a similar role to that
of PON1 in the metabolism of lipids and lipoproteins (1). 
There are two polymorphisms in the PON1 coding region:
leucine/methionine at position 55 (M55L) and glutamine/
arginine at position 192 (Q192R). PON2 also has two com-
mon polymorphic sites in the coding region: alanine/glycine
at position 148 (G148A) and cysteine/serine at position 311
(C311S) (4). These polymorphisms are associated with a num-
ber of pathophysiological conditions, such as coronary artery
disease, Parkinson’s disease, stroke, familial hypercholestero-
lemia, type 2 diabetes, late-onset Alzheimer’s disease, and
reduced bone mass in postmenopausal women (5-11). 
Various population studies have reported inter-ethnic dif-
ferences in the allele frequencies for PON1 and PON2 poly-
morphisms. This variability suggests that ethnic differences,
gene-gene interactions and susceptibility to environmental
factors might modulate the relationship between PON poly-
morphisms and the above mentioned diseases. Considering
the important contribution of these polymorphisms to genet-
ic susceptibility in atherosclerosis, and the variability in allele
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Paraoxonase Gene Polymorphism in South-western Korean Population
Paraoxonase (PON) has anti-atherogenic activity. Considering the important role of
polymorphism in the genetic susceptibility to cardiovascular disease and the vari-
ability of its allele frequencies in different ethnic groups, the distribution of genotypes
and allele frequencies of PON1M55L, PON1Q192R, PON2A148G, and PON2S311C
polymorphisms was analyzed in a total 988 South-western Koreans and determined
their effects on lipid parameters. The genotype distribution of PON1 at position 55
was LL=0.886, LM=0.114; and at position 192 was QQ=0.406, QR=0.594. The fre-
quencies of the PON1 55L allele and the PON1 192R allele were similar to those
seen in Chinese populations and Western populations, respectively. The genetic
distribution of PON2 at position 148 was AA=0.619, AG=0.345, GG=0.035; and at
position 311 was CC=0.035, SC=0.345, SS=0.619. The frequencies of the PON2
148G and 311S alleles were similar to those seen in Chinese populations. The con-
centrations of LDL and ApoB were significantly different between the PON2A148G
(P<0.05) and PON2 S311C polymorphisms (P<0.01). PON polymorphisms and
allele frequencies were described in Koreans living south-western part of Korea. These
ethnic variations are considered important in the interpretation of diseases associ-
ated with PON polymorphisms.
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Accepted : 28 July 2008frequencies among different ethnic groups, the aim of this
work was to evaluate the distribution of PON polymorphisms
and to determine their role association with lipid profiles in
a population living in South-western part of Korea. 
MATERIALS AND METHODS
Subjects
The allele distribution of the PON polymorphisms was
determined in 988 (519 males, 469 females) unrelated vol-
unteers, all of whom were hospital patients or outpatients
for health screening from South-west parts of Korea. Writ-
ten informed consent was obtained from each patient. This
study protocol was approved by the Institutional Review
Board of Chonbuk National University Hospital. 
Genotyping of DNA
Peripheral blood samples were collected after the consent.
DNA was extracted using Nucleon
� DNA extraction kits.
DNA samples were quantified using a GeneQuant II RNA/
DNA calculator (Amersham-Pharmacia Biotech, Uppsala,
Sweden), and 5-10 ng of DNA form each patient was ampli-
fied through a Hot Start polymerase chain reaction (PCR)
protocol. The primers applied for PON1 55 PCR and PON1
192 PCR were PON1-55F, PON1-55R, PON1-192F, and
PON1-192R, determining a 138 bp and a 151 bp PCR am-
plicon size, respectively. The primers applied for PON2 148
PCR and PON2 311 PCR were PON2-148F, PON2-148R,
PON2-311F, and PON2-311R, determining a 165 bp and
a 225 bp PCR amplicon size, respectively. The detection oli-
gonucleotide sets applied for PON1 55, PON1 192, PON2
148, and PON2 311 genotyping consisted of a 3′ fluorescein-
labeled anchor and either a 5′ -LC Red 705-labeled (PON1
192 mutation, PON2 148 mutation) or a 5′ -LC Red 640-
labeled (PON1 55 mutation, PON2 311 mutation) sensor
probe. The sequences of primers and probes, as well as the
applied fluorophores and nucleotide sets applied for the PON
genotyping with melting point analysis, are shown in Table
1. Both primers and fluorescently labeled probes were syn-
thesized by TIB MolBiol (Berlin, Germany). PCR and melt-
ing curve analysis were performed in 20 μ L volumes in glass
capillaries (Hoffmann-La Roche, Alameda, CA, U.S.A.). Dur-
ing PCR, the LightCycler automate (software version 4.5) con-
tinuously displays the current fluorescence and fluorescence
history of each capillary. Analysis of PCR products on agarose
gel and sequencing confirmed the presence of the specific
PCR products (data not shown). The observed melting point
temperature in PON1 55 MM was 63.0℃, PON1 55 LL
was 58℃, PON1 192 QQ was 63℃, PON1 192 RR was
57℃, PON2 148 AA was 64℃, PON2 148 GG was 58℃,
PON2 311 SS was 59℃, and PON2 311 CC was 53℃(5).
Both melting point temperatures were noted in heterozy-
gotes (PON1 55 LM, PON1 192QR, PON2 148 AG, PON2
311SC). 
Statistical analysis
Differences in demographic characteristics were compared
by univariate analysis using Student’s t test. Allele and geno-
type frequencies were calculated by gene counting. The chi-
square test was used both to estimate the Hardy-Weinberg
equilibrium and to compare the genotype and allele frequen-
cies between the sexes. Allele frequencies observed in the
Korean population were compared with those reported in
other populations using the Mantel-Haenszel chi-square test.
One-way analysis of variance (ANOVAR) was used to com-
pare the mean levels of lipid parameters among the different
genotypes. A value of P<0.05 was considered statistically
significant.
RESULTS
Clinical characteristics of study subjects are shown in Table
2. The mean age was 66.18±12.2 yr, with no age difference
between the sexes (male, n=519, 64.13±12.2 yr; female, n=
469, 67±12.4 yr; P=0.561). With respect to vascular disease
risk factors, a large proportion of individuals had hyperten-
sion. Genotype and allele frequencies for the PON1M55L,
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F, forward primer; R, reverse primer; LC Red 705, fluorophore LightCy-
cler Red 705; LC Red 640, fluorophore LightCycler Red 640.
Primers/probes Sequences
Primers
PON1-55F 5′ -CCTGCAATAATATGAAACAACCTG-3′
PON1-55R 5′ -CTAGAACACAGAAAAGTGAAAGAAAAC-3′
PON1-192F 5′ -TATTGTTGCTGTGGGACCTGAG-3′
PON1-192R 5′ -CCTTCTGCCACCACTCGAAC-3′
PON2-148F 5′ -ATGAGCAGCTTCCCATCA-3′
PON2-148R 5′ -CATGTACGGTGGTCTTATATTCATAC-3′
PON2-311F 5′ -TTCAACAGCATGTCCCCTTAA-3′
PON2-311R 5′ -CTTCCCATCATACACTGAGGCTA-3′
Probes
55-Sensor 5′ -CTCTGAAGACATGGAGATACTGCC-FL-3′
55-Anchor 5′ -LCRed640-ATGGACTGGCTTTCATTAGCTCTG-
TGAGGT-3′
192-Sensor 5′ -CCCCTACTTACAATCCTGGGAGAT-FL-3′
192-Anchor 5′ -LC705-ATTTGGGTTTAGCGTGGTCGTATGTTG-3′
148-Sensor 5′ -GAACATTCTATCTGAGAAGCCTACAGTG-FL-3′
148-Anchor 5′ -LC705-CTACAGTTTATGCCAACAATGGGTCTG-
TTC-3′
311-Sensor 5′ -CATCCAGAACATTCTATGTGAGAA-FL-3′
311-Anchor 5′ -LC640-CCTACAGTGACTACAGTTTATGCCAAC-3′
Table 1. Sequences of primers and probes, as well as the appli-
ed fluorochromes used for PON1 and PON2 genotyping through
melting point analysis on the LightCyclerPON1Q192R, PON2A148G, and PON2S311C polymor-
phisms are summarized in Table 3. Observed and expected
frequencies for the polymorphisms were at Hardy-Weinberg
equilibrium. In the case of the PON1 55 polymorphism, the
most frequent allele was L (94.3%), and the most common
genotype was the homozygote LL (88.6%). The most frequent
PON1 192 allele was Q (70.3%) and the most common geno-
type was heterozygote QR (59.4%). In the case of the PON2
148 polymorphism, the most frequent allele was A (79.2%),
and the most common genotype was the homozygote AA
(61.9%). The most frequent PON2 311 allele was S (79.2%),
and the most common genotype was homozygote SS (61.9%).
There was no significant difference between the sexes in terms
of genotype or allele frequency. The alle frequencies of PO-
N1M55L, PON1Q192R, PON2A148G, and PON2S311C
were compared in the Korean population to those previous-
ly described in other Asian (12-18), American (19-23) and
European (7, 8, 24-31) groups (Table 4). The PON1 55 L
allele frequencies in Asian populations were higher than in
other ethnic groups (P<0.05), and the allele frequency in Kore-
ans was higher than those seen in Thai, Iranian, and Pakis-
tani populations (P<0.05). The Korean population showed
a PON1 192Q allele frequency similar to that seen in other
ethnic groups, except for those of China, Taiwan, Mexico and
Latin America (P<0.05). The PON2 148 A allele frequency
in the Korean population was similar to that seen in other
populations, except for those of Pakistan and Brazil (P<0.005).
The PON2 311S allele frequency in the Korean population
was different compared to that of populations in Pakistan and
the U.S.A. (P<0.05). 
To determine the of PON gene polymorphisms on the lipid
profile, the lipid profile was classified as high, normal or low
according to the previously defined normal ranges (cholesterol,
0-200 mg/dL; triglyceride, 0-200 mg/dL; HDL cholesterol,
48.9-73.5 mg/dL; LDL cholesterol, 0-140 mg/dL; ApoAI,
1.08-2.24 g/L, ApoB 0.60-1.17 g/L; lipoprotein A, 0-30 mg/
dL; total homocysteine 5-20 μ M/L). There was no difference
in lipid profile among PON 1 polymorphisms, but the PON2
A148G and PON2S311C polymorphisms showed significant
differences in LDL and ApoB concentrations (P=0.023, P<
0.001) (Table 5). Homozygotes for PON2 148G and PON2
311 C showed higher concentrations of LDL cholesterol and
higher ApoB levels (Table 6).
DISCUSSION
Numerous studies have been conducted on the relation
between PON polymorphisms and genetic susceptibility to
coronary heart disease (CHD). PON1 has the capacity to in-
hibit LDL oxidation. The PON1 192R allele is positively
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Values are presented as mean±SD.
HDL, high density lipoprotein; Apo, apolipoprotein; Lpa, lipoprotein A. 
PON, paraoxonase.
Mean±SD
Age (yr) 66.18±12.20
Male (n [%]) 518 (52.5%)
Hypertension (n [%]) 451 (45.7%)
Diabetes mellitus (n [%]) 182 (18.4%)
Cholesterol (mg/dL) 190.0±42.04 
logcholesterol 2.3±0.10
Triglyceride (mg/d) 133.1±98.28 
logTG 2.0±0.24
HDL (mg/dL) 43.7±11.42
logHDL 1.6±0.11
LDL (mg/dL) 116.7±35.87
logLDL 2.0±0.13
Lpa (mg/dL) 35.1±28.09
logLPa 1.5±0.50
ApoAI (g/d) 1.2±0.26
ApoB (g/L) 0.9±0.25
HbA1C 6.2±1.26
Total Homocysteine (μ M/L) 2.0±0.27
Glucose (mg/dL) 146.8±59.98
Table 2. Study population characteristics (n=988)
Group
Genotypes
2 P Male
(n=519)
Female
(n=469)
Total
(n=988)
PON1M55L
LL 88.4% 88.7% 88.6%
LM 11.4% 11.3% 11.3% 0.91 0.64 
MM 0.1% 0.0% 0.1%
Allele
L 94.1% 94.3% 94.3%
M 5.8% 5.7% 5.7%
PON1Q192R
QQ 41.0% 40.1% 40.6% 0.09 0.76 
QR 59.0% 59.9% 59.4%
RR 0.0% 0.0% 0.0%
Allele
Q 70.5% 70.1% 70.3%
R 29.5% 29.9% 29.7%
PON2A148G
AA 60.7% 63.3% 61.9%
AG 35.1% 33.9% 34.5% 1.87 0.39 
GG 4.2% 2.8% 3.5%
Allele
A 78.3% 80.3% 79.2%
G 21.8% 19.8% 20.8%
PON2S311C
CC 4.2% 2.8% 3.5%
SC 35.1% 33.9% 34.5% 1.87 0.39 
SS 60.7% 63.3% 61.9%
Allele
C 21.8% 19.8% 20.8%
S 78.3% 80.3% 79.2%
Table 3. Genotype and allele frequencies of PON gene cluster
polymorphismsassociated with CHD while the Q allele is protective against
atherosclerosis (1). The majority of clinicians have studied
the PON1 Q192R polymorphism. On meta-analysis of PON
Q192R polymorphisms and CHD, a highly significant pos-
itive association was confirmed in the population with type
2 diabetes (32). Fewer studies have been conducted on the
PON1 L55M, PON2 A148G, and PON2 S311C polymor-
phisms in CHD, but the results have proved conflicting (2,
33). The major factor contributing of these differences is a
completely different distribution of PON polymorphisms
among different ethnic populations. 
In the present study, the allele and genotype frequencies
564 B.-S. Shin
Statistical significance between the world populations and the Korean population in this study was determined by means of the Mantel-Haenszel chi-
square test. PON, paraoxonase. 
Population References
M L P
PON1-55
R Q P
PON1-192
G A P
PON2-148
C S P
PON2-311
Korea (n=988) 0.941 0.058 - 0.705 0.295 - 0.7825 0.2175 - 0.7825 0.2175 - Present study
Japan (n=2,210) 0.927 0.073 0.774 0.666 0.334 0.614 -- 0.802 0.198 0.728 Yamada et al., 
2003 (13)
China (n=475) 1 0 0.013 0.352 0.648 <0.001 0.826 0.174 0.372 0.827 0.173 0.372 Wang et al., 2003 (12)
Taiwan (n=597) 0.972 0.028 0.306 0.359 0.641 <0.001 -- - --- Li et al., 2006 (14)
Thailand (n=202) 0.95 0.005 0.756 0.71 0.29 0.913 -- - - - - Phuntuwate et al., 
2005 (15)
Iran (n=132) 0.59 0.41 <0.001 0.69 0.31 0.841 -- - - - Sepahvand et al., 
2007 (16)
Pakistan (n=370) 0.783 0.217 0.001 0.672 0.328 0.614 0.51 0.49 0.001 0.388 0.612 <0.001 Saeed et al., 2007 (17)
Austria (n=303) 0.644 0.356 <0.001 0.746 0.254 0.455 -- - - - - Watzinger et al., 
2002 (18)
U.S.A. (n=2,553) 0.637 0.363 <0.001 0.72 0.28 0.79 0.766 0.234 0.866 0.233 0.767 <0.001 Ranade et al., 2005 (19)
Canada (n=324 ) 0.64 0.36 <0.001 0.73 0.27 0.671 0.76 0.24 0.737 --- McKeown-Eyssen et al., 
2004 (20)
Mexico (n=214) 0.84 0.16 0.024 0.51 0.49 0.005 -- ---- Rojas-Garcia et al.,
2005 (21)
Brazil (n=376) 0.64 0.36 <0.001 0.66 0.34 0.513 0.6 0.4 0.006 0.71 0.29 0.256 Oliveira et al., 2004 (22)
Latin America (n=260) 0.82 0.18 0.009 0.48 0.52 0.001 - -- - - - Holland et al., 2006 (23)
U.K. (n=405) 0.63 0.37 <0.001 0.71 0.29 0.913 0.73 0.27 0.411 0.74 0.26 0.508 Pasdar et al., 2006 (8)
Netherlands (n=201) 0.627 0.373 <0.001 0.677 0.323 0.724 -- ----Leus et al., 2001 (24)
Ireland (n=388) 0.65 0.35 <0.001 0.69 0.31 0.841 -- ---- Hasselwander et al.,
1999 (25)
Germany (n=535) 0.644 0.3566 <0.001 0.723 0.277 0.79 -- ---- Gardemann et al., 
2000 (26)
Italy (n=273) 0.601 0.399 <0.001 0.711 0.289 0.913 -- - 0.802 0.198 0.728 Martinelli et al., 2005 (27)
Poland (n=437) 0.64 0.36 <0.001 0.743 0.257 0.5578 -- - 0.76 0.24 0.737 Slowik et al., 2007 (7)
Turkey (n=116) 0.702 0.298 <0.001 0.6214 0.3785 0.214 -- ---- Agachan et al., 2005 (28)
Israel (n=193) 0.583 0.417 <0.001 0.65 0.35 0.422 -- - 0.842 0.158 0.279 Karban et al., 2007 (29)
Spain (n=388) 0.626 0.374 <0.001 0.701 0.299 0.963 -- ----Ferre et al., 2003 (30)
Switzerland (n=199) 0.666 0.334 <0.001 0.666 0.334 0.614 -- ----Garin et al.,  2005 (31)
Table 4. PON polymorphism allele frequencies in various world populations compared with those found in the present study
PON2A148G
AA AG GG
PON2S311C
SS SC CC
LDLC
Normal 469 (47.5) 275 (27.9) 19 (1.9) P=0.023 469 (47.5) 275 (27.9) 19 (1.9) P=0.023
High 140 (14.2) 69 (7.0) 15 (1.5) 140 (14.2) 69 (7.0) 15 (1.5)
ApoB
Low 42 (4.2) 21 (2.1) 7 (0.7) P<0.001 42 (4.2) 21 (2.1) 7 (0.7) P<0.001
Normal  501 (50.8) 295 (29.9) 15 (1.5) 501 (50.8) 295 (29.9) 15 (1.5)
High 67 (6.8) 28 (2.8) 11 (1.1) 67 (6.8) 28 (2.8) 11 (1.1)
Table 5. Association between PON2 polymorphisms and lipid profile (n=988)
PON, paraoxonase; LDLC, low-density lipoproteins cholesterol; Apo, apolipoprotein. of PON polymorphisms were described in a south-western
Korean population. The frequencies were compared with
previously described frequencies in other populations. We
found no significant difference between the sexes with respect
to PON genotype distribution or allele frequency. Frequen-
cy distribution showed that the Korean population had a sim-
ilar distribution of POM1 55 polymorphisms compared to
the Asian population, with the exception of an increased fre-
quency of the L allele in the Korean population. The Kore-
an population had important differences in PON1 distribu-
tion when compared to American and European population
(P<0.05). With respect to the PON1 192 polymorphism,
the Korean population showed a frequency pattern similar
to that of other ethnic groups, with increased frequency of
the Q allele. However, this was significantly different com-
pared to populations from China and Taiwan. The genotype
distribution of PON2 polymorphism was narrower than that
seen in the PON1 polymorphism. PON2 A148G and PON2
S311C polymorphisms seen in the Korean population exhib-
ited a pattern similar to those seen in other ethnic groups,
with increased frequencies of A and S alleles. However, there
were significant distribution differences compared with pop-
ulations from Pakistan, Brazil, and the U.S.A. PON serum
concentration and activity are considered more important
than PON polymorphisms in the risk of atherosclerotic dis-
ease, and gene-gene and gene-environmental interaction may
increase or decrease susceptibility to the disease. Therefore,
these ethnic variations in PON polymorphisms could help
us to understand the role of PON as a marker for the inter-
pretation of data correlated with a specific disease. 
In order to determine the role of PON polymorphism in
the lipid profile of this study population, the lipid levels were
determined and the association of the PON polymorphisms
and lipid profiles was evaluated. In this analysis, no associa-
tion was found between PON1 genotypes and lipid concen-
tration (data not shown). However the PON2 polymorphism
was found to affect concentrations of LDL and ApoB. Homo-
zygotes for PON2 148G and PON2 311 C showed higher
concentrations of LDL cholesterol and higher ApoB levels
(P=0.017, 0.014, respectively). These findings differ from
previous reports. Homozygotes for PON2 148A and PON2
311S had significantly higher plasma total cholesterol and
LDL cholesterol and higher ApoB levels than homozygotes
for PON2 148G and PON2 311C and heterozygotes for
PON2 A148G and PON2 S311C (4). Another report found
that homozygotes for PON2 148G had the highest plasma
concentrations of total cholesterol, HDL cholesterol, and Ap-
oAI (34). Homozygotes of for PON2 311C was reported to
have the highest concentration of total cholesterol and LDL
cholesterol (24). These discrepancies suggest that polymor-
phisms in the PON gene are associated with significant vari-
ations in intermediate traits in plasma lipoprotein metabo-
lism, through an unknown mechanism. Additional studies
using large population based cohorts will be needed to deter-
mine the general applicability of the present results for Kore-
an population.
In this study, the PON polymorphisms and allele frequen-
cies were described in a Korean population, and compared
with other ethnic groups. These ethnic variations are consid-
ered important factors in the interpretation of diseases asso-
ciated with PON polymorphism. 
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